Effectiveness of Subcutaneous Versus Sublingual Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and Asthma: A Systematic Review

Chelladurai, Yohalakshmi; Suarez‐Cuervo, Catalina; Erekosima, Nkiruka; Kim, Julia M.; Ramanathan, Murugappan; Segal, Jodi B; Lin, Sandra Y.

doi:10.1016/j.jaip.2013.04.005

Cited by 71 publications

(54 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A systematic review of head-to-head comparison studies showed low-graded evidence of greater effectiveness of SCIT than SLIT for asthma symptoms and a composite of rhinitis symptoms and medication use [127].…”

Section: Sublingual Immunotherapymentioning

confidence: 99%

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Domínguez‐Ortega

Delgado

Blanco

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Asthma is frequently associated with atopy, characterized by the production of specific immunoglobulin E in response to environmental allergens. Currently, two types of allergen immunotherapy (AIT) are used in clinical practice: subcutaneous and sublingual immunotherapy, both accepted as key components of the therapeutic repertoire for allergic rhinitis and conjunctivitis. However, their role in asthma remains controversial. The present document is aimed at providing the clinicians with a review of the evidence on the use of AIT in asthma, focusing on the most relevant aspects of its mechanism of action, its efficacy, and existing data on safety, tolerability, and cost-effectivity, both in pediatric and adult populations. A systematic search of MEDLINE, Cochrane, and Clinical Trials databases from 2000 to April of 2016 was carried out by a panel of experts from the Spanish Allergy and Clinical Immunology Scientific Society. Relevant studies prior to the year 2000 included in ulterior systematic reviews were also considered. More than 4000 articles were identified during the search and 241 were selected to retrieve available evidence on AIT, which was graded according to the Oxford classification. All the group members reviewed the resulting text until the final version reached the consensual agreement. A summary of recommendations on the more relevant topics are proposed. The role of AIT as a valuable therapeutic strategy for prevention of exacerbation and progressive decline in lung function is highlighted. Future research should include specific tools for asthma evaluation when assessing AIT effectiveness in asthmatic patients. ResumenEl asma se asocia frecuentemente con alergia, entendida ésta como la producción de IgE específica frente a alérgenos ambientales. Actualmente, existen dos tipos de inmunoterapia específica con alérgenos (ITE) para la práctica clínica habitual: subcutánea y sublingual, ambas indicadas en el tratamiento de la rinitis y la conjuntivitis alérgicas. Sin embargo, su papel en el asma resulta todavía controvertido. Dominguez-Ortega J, et al.

show abstract

Section: Sublingual Immunotherapymentioning

confidence: 99%

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Domínguez‐Ortega

Delgado

Blanco

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

show abstract

“…Similarly, another review examining the effect of SLIT on asthma reported that eight of the 13 studies which examined this association reported greater than 40 % improvement in asthma symptoms [69]. Regarding SCIT vs SLIT, the best route of immunotherapy delivery has yet to be established, but limited evidence thus far supports SCIT over SLIT for reduction of asthma and AR symptoms [71]. …”

Section: Reviewmentioning

confidence: 99%

Allergic rhinitis: the “Ghost Diagnosis” in patients with asthma

Egan

Bunyavanich

2015

asthma res and pract

View full text Add to dashboard Cite

Allergic rhinitis (AR) is a common comorbidity of asthma that contributes to asthma severity. Although over 80 % of asthmatics have AR, the condition is frequently underdiagnosed in subjects with asthma. AR itself is also a highly prevalent condition, affecting 10-30 % of adults and up to 40 % of children. AR has been associated with both increased risk of asthma development and asthma severity. The exact mechanisms underlying these relationships have yet to be fully elucidated, but evidence supports a role for allergen sensitization. Compared to those with asthma alone, patients with comorbid AR and asthma have greater use of health care resources, including visits to the general practitioner, emergency department and hospitalizations. Pharmacological treatment of AR reduces this health care burden. Immunotherapy for AR improves both asthma and rhinitis symptoms in addition to preventing future allergen sensitizations and asthma development. Appropriate recognition, diagnosis and treatment of AR can significantly reduce asthma morbidity and improve quality of life.

show abstract

“…Recently published review articles and meta-analyses have compared the efficacy of different treatment modalities, with some mixed conclusions in the comparison between SCIT and SLIT. Chelladurai et al 18 reviewed available head-to-head trials of SCIT compared with SLIT and concluded that there is moderate grade evidence favoring SCIT for reduction in symptoms of AR and low-grade evidence favoring SCIT in reducing allergic asthma symptoms. In the pediatric population, Kim et al 19 reviewed studies of SCIT and SLIT for the treatment of asthma and allergic rhinoconjunctivitis.…”

mentioning

confidence: 99%

Network Meta-analysis Shows Commercialized Subcutaneous and Sublingual Grass Products Have Comparable Efficacy

Nelson¹,

Cartier²,

Allen‐Ramey³

et al. 2015

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

Effectiveness of Subcutaneous Versus Sublingual Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and Asthma: A Systematic Review

Cited by 71 publications

References 23 publications

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Allergic rhinitis: the “Ghost Diagnosis” in patients with asthma

Network Meta-analysis Shows Commercialized Subcutaneous and Sublingual Grass Products Have Comparable Efficacy

Contact Info

Product

Resources

About